[1]张　婷,刘起鹏,郭婉莹,等.曲妥珠单抗联合术前新辅助化学治疗对乳腺癌患者肿瘤标志物、血管内皮因子和凋亡因子的影响及疗效观察[J].新乡医学院学报,2020,37(11):1075-1079.[doi:10.7683/xxyxyxb.2020.11.016]
　ZHANG Ting,LIU Qipeng,GUO Wanying,et al.Effect of trastuzumab combined with neoadjuvant chemotherapy on tumor markers,vascular endothelial growth factor and apoptotic factors in patients with breast cancer and therapeutic effect analysis[J].Journal of Xinxiang Medical University,2020,37(11):1075-1079.[doi:10.7683/xxyxyxb.2020.11.016]
点击复制

曲妥珠单抗联合术前新辅助化学治疗对乳腺癌患者肿瘤标志物、血管内皮因子和凋亡因子的影响及疗效观察
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
37
期数:
2020年11
页码:
1075-1079
栏目:
临床研究
出版日期:
2020-11-05

文章信息/Info

Title:
Effect of trastuzumab combined with neoadjuvant chemotherapy on tumor markers,vascular endothelial growth factor and apoptotic factors in patients with breast cancer and therapeutic effect analysis
作者:
张　婷; 刘起鹏; 郭婉莹; 李　鹏; 乔伟强; 邓　淼
（河南科技大学第一附属医院乳腺外科，河南　洛阳　471003）
Author(s):
ZHANG Ting; LIU Qipeng; GUO Wanying; LI Peng; QIAO Weiqiang; DENG Miao
(Department of Breast Surgery,the First Affiliated Hospital of Henan University of Science and Technology,Luoyang 471003,Henan Province,China)
关键词:
乳腺癌; 曲妥珠单抗; 新辅助化学治疗; 肿瘤标志物
Keywords:
breast cancer; trastuzumab; neoadjuvant chemotherapy; tumor markers
分类号:
R737.9
DOI:
10.7683/xxyxyxb.2020.11.016
文献标志码:
A
摘要:
目的　探讨曲妥珠单抗联合术前新辅助化学治疗对乳腺癌患者肿瘤标志物、血管内皮因子和凋亡因子的影响及治疗效果。方法　选择2015年1月至2018年7月河南科技大学第一附属医院收治的人表皮生长因子受体-2阳性乳腺癌患者80例为研究对象，依据治疗方式不同分为对照组和观察组，每组40例。对照组患者给予吡柔比星、环磷酰胺联合多西他赛方案进行术前新辅助化学治疗，21 d为1个周期，共6个周期；观察组患者在此基础上联合曲妥珠单抗治疗，21 d为1个周期，共4个周期。2组患者均于治疗前、后抽取空腹外周静脉血，采用酶联免疫吸附试验法检测血清癌胚抗原（CEA）、糖类抗原153（CA153）、血管内皮生长因子A（VEGFA）、血管内皮生长因子B（VEGFB）及血管内皮生长因子C（VEGFC）水平，采用Western blot检测诱骗受体3（DcR3）及环氧化酶-2 (COX-2)蛋白表达水平；观察2组患者完全缓解（CR）、部分缓解（PR）、稳定（SD）、恶化（PD）以及化学治疗后的病理完全缓解(pCR)情况，比较2组患者缓解率（RR）和pCR率。结果　治疗前，2组患者血清CEA、CA153、VEGFA、VEGFB、VEGFC水平及DcR3，COX-2蛋白表达水平比较差异均无统计学意义（P>0.05）。治疗后，2组患者血清CEA、CA153、VEGFA、VEGFB、VEGFC水平及DcR3，COX-2蛋白表达水平均显著低于治疗前（P<0.05）。治疗后，观察组患者血清CEA、CA153、VEGFA、VEGFB、VEGFC水平及DcR3，COX-2蛋白表达水平均显著低于对照组（P<0.05）。观察组患者RR和pCR率分别为75.00%（30/40）、45.00%（18/40），对照组患者RR和pCR率分别为45.00%（18/40）、20.00%（8/40），观察组患者RR和pCR率均显著高于对照组（P<0.05）。结论　曲妥珠单抗联合新辅助化学治疗可有效降低乳腺癌患者血清肿瘤标志物、血管内皮因子及凋亡相关分子表达水平，提高近期疗效。
Abstract:
Objective　To investigate the effect of trastuzumab combined with neoadjuvant chemotherapy on tumor markers,vascular endothelial growth factor and apoptotic factors in patients with breast cancer and its therapeutic effect.Methods　Eighty patients with human epidermalgrowth factor receptor-2 positive breast cancer admitted to the First Affiliated Hospital of Henan University of Science and Technology from January 2015 to July 2018 were selected as the research subjects.They were divided into the control group and the observation group according to different treatment methods,with 40 cases in each group.The patients in the control group were treated with pirirubicin,cyclophosphamide and docetaxel for neoadjuvant chemotherapy,and the patients were treated for six treatment cycles（21 days were a treatment cycle）；the patients in the observation group were treated with trastuzumab on the basis of neoadjuvant chemotherapy consistent with the control group,and the patients were treated for treatment cycles (21 days were a treatment cycle).Fasting peripheral venous blood was drawn before and after treatment in both groups,the enzyme linked immunosorbent assay was used to detect the serum carcinoembryonic antigen (CEA),carbohydrate antigen 153(CA153),vascular endothelial growth factor A (VEGFA),vascular endothelial growth factor B (VEGFB),vascular endothelial growth factor C (VEGFC);and Western blot was used to detect the levels of decoy receptor 3(DcR3) and cyclooxygenase-2(COX-2) protein.The short-term effects of the two groups were observed,including complete remission(CR),partial mitigation(PR),stable disease (SD),progression disease (PD),the remission rate (RR) and complete pathological remission (pCR) rate were compared between the both groups.Results　Before treatment,there was no significant difference in the levels of CEA,CA153,VEGFA,VEGFB,VEGFC and DcR3,COX-2 protein between the two groups (P>0.05).After treatment,the levels of CEA,CA153,VEGFA,VEGFB,VEGFC and DcR3,COX-2 protein in both groups were significantly lower than those before treatment (P<0.05).After treatment,the levels of CEA,CA153,VEGFA,VEGFB,VEGFC and DcR3,COX-2 protein in the observation group were significantly lower than those in the control group(P<0.05).The RR and pCR rate of patients in the observation group were 75.00%(30/40),45.00%(18/40),respectively;the RR and pCR rate in the control group were 45.00%(18/40),20.00%(8/40),respectively.The RR and pCR rate of patients in the observation group were significantly higher than those in the control group(P<0.05).Conclusion　Trastuzumab combined with neoadjuvant chemotherapy can effectively reduce the expression levels of tumor markers,vascular endothelial factors and apoptosis-related molecules in serum,and improve the short-term efficacy.

参考文献/References:

［1］　常伟,丁敏,周建华,等.曲妥珠单抗联合紫杉醇治疗人表皮生长因子受体-2过表达转移性乳腺癌的疗效和安全性评价［J］.新乡医学院学报,2018,35(6):517-520.
［2］　HAHN S Y,KO E Y,HAN B K,et al.Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy［J］.Eur J Radiol,2014,83(2):283-288.
［3］　ZHAO J,FENG S S.Effects of PEG tethering chain length of vitamin E TPGS with a herceptin-functionalized nanoparticle formulation for targeted delivery of anticancer drugs［J］.Biomaterials,2014,35(10):3340-3347.
［4］　GIANNI L,EIERMANN W,SEMIGLAZOV V,et al.Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH):follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort［J］.Lancet Oncol,2014,15(6):640-647.
［5］　中华人民共和国国家卫生和计划生育委员会.原发性乳腺癌规范化诊疗指南（试行）［J］.中国医学前沿杂志：电子版,2013,5 (5):30-37.
［6］　VIVEK R,THANGAM R,NIPUNBABU V,et al.Multifunctional HER2-antibody conjugated polymeric nanocarrier-based drug delivery system for multi-drug-resistant breast cancer therapy［J］.ACS Appl Mater Inter,2014,6(9):6469-6480.
［7］　YANG Q,LI L,ZHANG J,et al.A computerized global MR image feature analysis scheme to assist diagnosis of breast cancer:a preliminary assessment［J］.Eur J Radiol,2014,83(7):1086-1091.
［8］　LIU P,CAI Z,KANG J W,et al.Intracellular routing in breast cancer cells of streptavidin-conjugated trastuzumab fab fragments linked to biotinylated doxorubicin-functionalized metal chelating polymers［J］.Biomacromolecules,2014,15(3):715-725.
［9］　OWEN S C,PATEL N,LOGIE J,et al.Targeting HER2 + breast cancer cells:lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles［J］.J Controll Release,2013,172(2):395-404.
［10］　AVDIN R S.Herceptin-decorated salinomycin-loaded nanoparticles for breast tumor targeting［J］.J Biomed Mater Res A,2013,101(5):1405-1415.
［11］　刘霞,高薇.赫赛汀联合新辅助化疗治疗 HER-2阳性乳腺癌26例疗效分析及护理［J］.齐鲁护理杂志,2016,22(9):74-76.
［12］　安雪青,吕健东,苏锋,等.血清SDF-1联合CXCL5及CEA联合检测用于乳腺癌诊断的敏感度与特异性分析［J］.中国实验诊断学,2018,22(1):10-13.
［13］　李玉柱,张玉敏,韩龙才,等.CEA、CA153、TPS、Fer、CYFRA21-1检测在乳腺癌术后转移中的诊断价值［J］.实用医学杂志,2017,33(22):3810-3814.
［14］　TSAI H T,ISAACS C,FU A Z,et al.Risk of cardiovascular adverse events from trastuzumab (Herceptin(?)) in elderly persons with breast cancer:a population-based study［J］.Breast Cancer Res Treat,2014,144(1):163-170.
［15］　陈旭坚.血清肿瘤标志物CEA、CA125、CA15-3对Herceptin联合TAX治疗Her-2过表达晚期乳腺癌的疗效预测［D］.广州：南方医科大学,2010.
［16］　LIU H,JIANG Y,DAI Q,et al.Peripheral enhancement of breast cancers on contrast-enhanced ultrasound:correlation with microvessel density and vascular endothelial growth factor expre-ssion［J］.Ultrasound Med Biol,2014,40(2):293-299.
［17］　SHENG E W,YONG H,KUN H,et al.A highly sensitive and selective aptasensor based on fluorescence polarization for the rapid determination of oncoprotein vascular endothelial growth factor (VEGF)［J］.Anal Methods,2014,6(1):62-66.
［18］　郑林静.曲妥珠单抗对乳腺癌术后新辅助化疗患者血清TIMP-1/2、MMP-2/9的影响［J］.实用癌症杂志,2019,34(9):1424-1427.
［19］　CHEN H,ZHANG J J,GAO Y M,et al.Sensitive cell apoptosis assay based on caspase-3 activity detection with graphene oxi-deassisted electrochemical signal amplification［J］.Biosens Bioe-lectron,2015,68:777-782.
［20］　JIANG B,HUANG X,YAO H,et al.Discovery of potential anti-inflammatory drugs:diaryl-1,2,4-triazoles bearing N-hydroxyurea moiety as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase［J］.Org Biomol Chem,2014,12(13):2114-2127.
［21］　YANG C Y,LIN C K,HSIEH C C,et al.Anti-oral cancer effects of triptolide by downregulation of DcR3 in vitro,in vivo,and in preclinical patient-derived tumor xenograft model［J］.Head Neck,2019,41(5):1260-1269.
［22］　SHEISHAI H A,EL-WAHED M A,AIAD H A,et al.Prognostic impact of expression of forkhead boxp3 (FOXP3) and cyclooxygenase-2 (COX2) in breast cancer:a single-institutional study［J］.Breast,2019,44:S30-S31.

相似文献/References:

[1]张光谋,吴俊琢,徐振平,等.抗细胞凋亡基因bcl一2在乳腺癌中的表达[J].新乡医学院学报,2001,18(03):160.
[2]刘玉生 ． 万里,李森恺.乳腺癌切除即期乳房再造[J].新乡医学院学报,2001,18(01):023.
[3]王承正,张锦瑜,邱树升,等.C—erbB一2与ER、PS一2在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[4]王承正,张锦瑜,邱树升,等.C2erbB22 与ER、PS22 在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[5]王志民,段西华,祁天义,等.多点皮瓣固定法预防乳腺癌术后皮下积液效果观察 [J].新乡医学院学报,2007,24(03):287.
[6]郭兰青.乳腺癌患者生活质量影响因素[J].新乡医学院学报,2008,25(06):637.
[7]曹兴玥,赵庆伟,靳艳,等.CD44和nm23在乳腺浸润性导管癌中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):042.
[8]靳艳,曹兴玥,赵庆伟,等.CD62P在人乳腺癌组织中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):045.
[9]王　乐,王静萱,张清媛.乳腺癌骨转移靶向治疗进展[J].新乡医学院学报,2015,32(09):887.
[10]杨绍英,刘朝荣,张志刚,等.乳腺癌新辅助化学治疗前后雌激素受体、乳激素受体、Ki-67抗原和人类表皮生长因子受体-2的表达[J].新乡医学院学报,2017,34(2):125.[doi:10.7683/xxyxyxb.2017.02.012]
　YANG Shao-ying,LIU Chao-rong,ZHANG Zhi-gang,et al.Expressions of estrogen receptor，progestin recetor，Ki-67 antigen，and human epidermal growth factor receptor 2 before and after neoadjuvant chemotherapy in patients with breast cancer[J].Journal of Xinxiang Medical University,2017,34(11):125.[doi:10.7683/xxyxyxb.2017.02.012]
[11]李小峰,孙新宇,张　慧.曲妥珠单抗联合紫杉醇和卡铂治疗人表皮生长因子受体-2阳性乳腺癌的疗效及其对心功能的影响[J].新乡医学院学报,2022,39(4):376.[doi:10.7683/xxyxyxb.2022.04.016]
　LI Xiaofeng,SUN Xinyu,ZHANG Hui.Effect of trastuzumab combined with paclitaxel and carboplatin in the treatment of patients with human epidermal growth factor receptor-2-positive breast cancer and its effect on cardiac function[J].Journal of Xinxiang Medical University,2022,39(11):376.[doi:10.7683/xxyxyxb.2022.04.016]
[12]杨金伟,马楠楠,屈重阳,等.曲妥珠单抗对人表皮生长因子受体-2阳性乳腺癌患者的心血管毒性研究进展[J].新乡医学院学报,2022,39(4):396.[doi:10.7683/xxyxyxb.2022.04.020]
　YANG Jinwei,MA Nannan,QU Chongyang,et al.Research progress on cardiovascular toxicity of trastuzumab in patients with human epidermal growth factor receptor-2 positive breast cancer[J].Journal of Xinxiang Medical University,2022,39(11):396.[doi:10.7683/xxyxyxb.2022.04.020]

更新日期/Last Update: 2020-11-05